Table 2 Objective responses (n = 71).

From: A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer

 

N (%)

95% CI

Complete response

9 (12.7)

6.8–22.4

Partial response

50 (70.4)

59.0–79.8

Stable disease

10 (14.1)

7.8–24.0

Progressive disease

0 (0)

 

Not evaluable

2 (2.8)

 

Objective response rate

59 (83.1)

72.7–90.1

Back to article page